• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Good News to Cancer Patients --- Metabolic Research and Cornerstone Pharmaceuticals Conduct a New Animal Study

Posted on: Monday, 27 August 2007, 09:13 CDT

Metabolic Research, Inc. (OTCBB: MTBR) announced today that an animal study conducted in cooperation with Cornerstone Pharmaceuticals, Inc. of Cranbury, NJ, confirmed that "ABL-SA" protein found in a Brazilian mushroom (a key component in Metabolic Research's Polimmune™ supplement) is effective in avidly binding to particularly aggressive lung cancer cells called H460, in mice.

The protein has the ability to identify cancer cells in the body, and stick to them. It then blocks the cancer cells' ability to survive. An earlier in vitro study using HT29 colon cancer demonstrated an 81% inhibition rate of this type of cancer proliferation. In other words, "81% of cancer cells died during the test," says Dr. David Summers, President and CEO of Metabolic Research, Inc.

The most recent animal studies demonstrate that the protein began binding and being taken into the cancer cells within ten minutes of administration. The uptake of the single dose effectively peaked at two hours, and then dropped off to baseline after six hours.

"There was no apparent toxicity. This protein offers remarkable promise for future pharmaceutical development as the data shows that it avidly seeks out and binds to the tumor antigen and that this TF antigen is common to most epithelial cancers," said Dr. Summers.

The protein is currently a component in Metabolic Research's Polimmune™ dietary supplement. However, Metabolic Research may now develop the protein, according to FDA guidelines, as a natural dietary adjunct for cancer treatment.

"As an adjunct to already approved FDA cancer therapies, a Generally Regarded as Safe (GRAS) natural compound, such as this, would only have to be proven safe when used in combination with current treatment regimens. This means that this product could become available within months instead of years," stated Dr. Robert G.L. Shorr, PhD.

Metabolic Research Inc. is staffed by an international team dedicated to developing natural pharmaceutical-grade supplements through unique growing techniques. The result is the production of extremely safe and specific supplements containing the proteins, carbohydrates and fats for achieving specific internal health and balance without toxic contaminates such as mercury, lead, and PCBs. For more information about their techniques, see www.metabolicresearchinc.com.

For more information on Cornerstone Pharmaceuticals and Dr. Shorr, visit http://www.cornerstonepharma.com/biorob.html

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes,""belief,""expects,""intends,""anticipates,""will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the company's reports and registration statements filed with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category